Locations:
Search IconSearch
April 16, 2024/Cancer

Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Women's health physician

Primary (or premature) ovarian insufficiency not only affects a woman’s fertility but puts her health at risk. Unfortunately, it often is undiagnosed, and impacts many women under age 40. This condition often occurs as a result of treatment with certain alkylating and chemotherapy agents and/or radiation therapy at levels above 2-3 Gy (particularly those affecting the brain or pelvis).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Working on one of the largest interdisciplinary teams specializing in the management of menopause, Pelin Batur, MD, with the Center for Specialized Women’s Health is very familiar with the condition.

“In the medical community, there often isn’t a high degree of suspicion for primary ovarian insufficiency, so it may go unrecognized, but it’s important to identify and treat it,” says Dr. Batur. “Early loss of estrogen before age 40 is associated with many negative outcomes, such as low bone mass, cardiovascular disease, sexual dysfunction and neurological conditions such as dementia and Parkinson's disease.”

Educating patients

When patients are first diagnosed with cancer, they’re understandably facing information overload. But Dr. Batur notes it’s a good idea to have a conversation early on with female patients that treatment may impact their ovaries. This way, the issue is on their radar and they know what to watch for. Likewise, asking patients about their menses during and after treatment should be part of cancer follow-up care. “If a patient is young and their menses have become irregular or stopped, they deserve to have more of a conversation and lab testing to see what’s going on,” Dr. Batur says.

Clinicians should also be aware that spontaneous ovulation occurs in roughly half the cases of primary ovarian insufficiency. In fact, spontaneous rates of pregnancy are 5-10% in these individuals who have been previously told that they have "premature menopause." This is where open dialogue with the patient is essential to explain the potential for pregnancy and to discuss contraceptive options if needed.

Advertisement

What to watch for

If a clinician has a patient who is having irregular menses that have been going on for more than three or four months, checking the following labs is warranted.

  • Follicle-stimulating hormone (FSH) test
  • Thyroid levels
  • Prolactin levels, since this brain hormone can mimic early menopause
  • Estrogen levels (not needed to make a diagnosis, but can support diagnosis)

For patients less than 40 years of age, if their FSH is 25 mIU/mL or greater, there's no thyroid issue or other medical condition to explain loss of estrogen and the patient isn’t taking birth control pills, labs should be checked again a month later. If menses remain irregular and the FSH remains elevated, the patient would be diagnosed with primary ovarian insufficiency. For patients aged 40-45, this would be considered perimenopause or early menopause.

Symptoms can be far ranging. Low estrogen levels are associated with mood changes, insomnia, hair loss, body aches, vaginal dryness, low sex drive, night sweats and trouble concentrating.

Treatments

In general, if a patient loses estrogen before age 40 and there’s no compelling medical reason not to give it back, it’s advantageous to prescribe hormone replacement therapy. “This should not be confused with typical hormone therapy that's given to women in their 50s and 60s,” explains Dr. Batur. “For women ages 50+, typical menopausal hormone therapy can impact clotting and breast cancer risks with prolonged use. But these risks are not the same for young women who are meant to have high hormone levels naturally, until the natural age of menopause at 52.”

Advertisement

Hormone replacement therapy can be administered systemically via a higher-dose vaginal ring, skin patch, skin gel or oral pill. This treatment can help with symptom management in addition to protecting bone and heart health.

There are a few exceptions to treating with hormone replacement therapy, such as patients who have had estrogen-sensitive cancer. In those cases, non-hormone options need to be considered.

There is a high risk of osteoporosis for those with premature loss of estrogen, so patients should receive baseline and then periodic DXA scans to check bone density.

Primary ovarian insufficiency can also have a widespread mental and physical toll on patients. Bringing together a care team, including hormone specialists as well as those providing psychological support, is beneficial to help improve patients’ quality of life.

Advertisement

Related Articles

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Baby's feet
April 3, 2025/Cancer/News & Insight
Fertility Preservation Counseling for Young Adults with Cancer

Growing need for addressing fertility concerns

Ad